Redefining HDAC6 Therapeutics
Founded in 2019 as a spin-off from VIB and KU Leuven, Augustine Therapeutics is pioneering a new era in HDAC6-targeted drug development. Our work builds on the groundbreaking research of Prof. Ludo Van Den Bosch, who uncovered HDAC6’s critical role in peripheral neuropathies like Charcot-Marie-Tooth (CMT) disease and Chemotherapy-Induced Peripheral Neuropathy (CIPN), as well as neurodegenerative disorders such as ALS.
"This lab's pioneering research into Charcot-Marie-Tooth disease (CMT) is what led to the creation of Augustine Therapeutics. From the lab to the clinic, we're working hard to develop a CMT therapy…”
Why Augustine?
Our name is inspired by a famous patient of Jean-Martin Charcot, one of the first to identify the hereditary neuropathy now known as Charcot-Marie-Tooth disease.
CMT is a devastating disorder that progressively weakens muscles, causes severe pain, and lacks any approved treatments. Our mission is to change that—bringing transformative therapies to patients suffering from complex neurological diseases.
"As a patient, working in the Van Den Bosch Lab and seeing the genesis of Augustine Therapeutics has been very special for me. It focuses on a currently untreatable disease that unfortunately runs in my family. I know the future is bright for Charcot-Marie-Tooth disease"
Our Team
Augustine Therapeutics is led by a team of visionary scientists, experienced drug developers, and industry leaders dedicated to reshaping HDAC6-targeted medicine.
.png)
Investors
